News from a former Ambassador Award Honoree: Amicus Therapeutics Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038

Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expire in 2038

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,304,940, which is directed to a composition of matter covering migalastat (Galafold®).

The new U.S. patent titled “Methods of Treating Fabry Patients Having Renal Impairments” is directed to a molecule comprising migalastat bound to an alpha-galactosidase A protein and expires in 2038.

Read More

Acumen Analytics Launches ‘Life Sphere’ A New Podcast Dedicated to the People in Life Sciences.

The podcast features experts and advocates discussing trends, tools, careers and all components of the Life Sciences industry.

The first episodes of season one will be available May 3. New episodes will be released on Tuesdays. To learn more about Life Sphere, check the Acumen website for more details as they become available

Jefferson Health and Bayada to take ‘revolutionary step’ in home care with new joint venture
Philadelphia Business Journal 

Jefferson Health and Bayada Home Health Care entered into a definitive agreement Tuesday to form a joint venture that will accelerate the transformation of post-acute care and digital health.

The joint venture, tentatively called “Jefferson Health at Home,” will serve Jefferson home care patients in New Jersey and Pennsylvania.

Read More